The development of influenza A virus (IAV) vaccines, which elicits cross-strain immunity against seasonal and pandemic viruses is a major public health goal. As pigs are susceptible to human, avian, and swine-adapted IAV, they would be key targets of so called universal IAV vaccines, for reducing both the zoonotic risk and the economic burden in the swine industry. They also are relevant preclinical models. However, vaccination with conserved IAV antigens (AGs) in pigs was reported to elicit disease exacerbation. In this study, we assessed whether delivery strategies, i.e., dendritic cell (DC) targeting by the intradermal (ID) or intramuscular (IM) routes, impact on the outcome of the vaccination with three conserved IAV AGs (M2e, NP, and HA2) in pigs. The AGs were addressed to CD11c by non-covalent binding to biotinylated anti-CD11c monoclonal antibody. The CD11c-targeted AGs given by the ID route exacerbated disease. Conversely, CD11c-targeted NP injected by the IM route promoted T cell response compared to non-targeted NP. Furthermore, the conserved IAV AGs injected by the IM route, independently of DC targeting, induced both a reduction of viral shedding and a broader IgG response as compared to the ID route. Our findings highlight in a relevant animal species that the route of vaccine delivery impacts on the protection induced by conserved IAV AGs and on vaccine adverse effects. Finally, our results indicate that HA2 stands as the most promising conserved IAV AG for universal vaccine development.

INRA UE1277 Plate Forme d'Infectiologie Expérimentale PFIE Nouzilly France

Institut Pasteur Unité de Régulation Immunitaire et Vaccinologie Equipe Labellisée Ligue Contre le Cancer Paris France; INSERM U1041 Unité de Régulation Immunitaire et Vaccinologie Département Immunologie Paris France

Institute of Microbiology of the Czech Academy of Sciences v v i Prague Czech Republic

VIM INRA Université Paris Saclay Jouy en Josas France

Erratum v

Front Immunol. 2017 Jul 18;8:831. doi: 10.3389/fimmu.2017.00831. PubMed

Zobrazit více v PubMed

Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in influenza infection. Emerg Infect Dis (2006) 12(1):48–54.10.3201/eid1201.051237 PubMed DOI PMC

Macleod MK, David A, Jin N, Noges L, Wang J, Kappler JW, et al. Influenza nucleoprotein delivered with aluminium salts protects mice from an influenza A virus that expresses an altered nucleoprotein sequence. PLoS One (2013) 8(4):e61775.10.1371/journal.pone.0061775 PubMed DOI PMC

Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, Xu L, et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine (2005) 23(46–47):5404–10.10.1016/j.vaccine.2005.04.047 PubMed DOI

Li Z, Gabbard JD, Mooney A, Gao X, Chen Z, Place RJ, et al. Single-dose vaccination of a recombinant parainfluenza virus 5 expressing NP from H5N1 virus provides broad immunity against influenza A viruses. J Virol (2013) 87(10):5985–93.10.1128/JVI.00120-13 PubMed DOI PMC

Wu F, Huang JH, Yuan XY, Huang WS, Chen YH. Characterization of immunity induced by M2e of influenza virus. Vaccine (2007) 25(52):8868–73.10.1016/j.vaccine.2007.09.056 PubMed DOI

Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine (2004) 22(23–24):2993–3003.10.1016/j.vaccine.2004.02.021 PubMed DOI

Nachbagauer R, Miller MS, Hai R, Ryder AB, Rose JK, Palese P, et al. Hemagglutinin stalk immunity reduces influenza virus replication and transmission in ferrets. J Virol (2015) 90(6):3268–73.10.1128/JVI.02481-15 PubMed DOI PMC

Stanekova Z, Adkins I, Kosova M, Janulikova J, Sebo P, Vareckova E. Heterosubtypic protection against influenza A induced by adenylate cyclase toxoids delivering conserved HA2 subunit of hemagglutinin. Antiviral Res (2012) 97(1):24–35.10.1016/j.antiviral.2012.09.008 PubMed DOI

DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med (2014) 20(2):143–51.10.1038/nm.3443 PubMed DOI PMC

Breathnach CC, Clark HJ, Clark RC, Olsen CW, Townsend HG, Lunn DP. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge. Vaccine (2006) 24(8):1180–90.10.1016/j.vaccine.2005.08.091 PubMed DOI

Ma W, Kahn RE, Richt JA. The pig as a mixing vessel for influenza viruses: human and veterinary implications. J Mol Genet Med (2008) 3(1):158–66. PubMed PMC

Smith GJ, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybus OG, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature (2009) 459(7250):1122–5.10.1038/nature08182 PubMed DOI

Heinen PP, Rijsewijk FA, de Boer-Luijtze EA, Bianchi AT. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol (2002) 83(Pt 8):1851–9.10.1099/0022-1317-83-8-1851 PubMed DOI

Maroof A, Yorgensen YM, Li Y, Evans JT. Intranasal vaccination promotes detrimental Th17-mediated immunity against influenza infection. PLoS Pathog (2014) 10(1):e1003875.10.1371/journal.ppat.1003875 PubMed DOI PMC

Melero JA. Influence of antigen conformation and mode of presentation on the antibody and protective responses against human respiratory syncytial virus: relevance for vaccine development. Expert Rev Vaccines (2016) 15:1319–25.10.1080/14760584.2016.1175941 PubMed DOI

Radford KJ, Tullett KM, Lahoud MH. Dendritic cells and cancer immunotherapy. Curr Opin Immunol (2014) 27:26–32.10.1016/j.coi.2014.01.005 PubMed DOI

Lehmann CH, Heger L, Heidkamp GF, Baranska A, Luhr JJ, Hoffmann A, et al. Direct delivery of antigens to dendritic cells via antibodies specific for endocytic receptors as a promising strategy for future therapies. Vaccines (Basel) (2016) 4(2):E8.10.3390/vaccines4020008 PubMed DOI PMC

Kastenmuller W, Kastenmuller K, Kurts C, Seder RA. Dendritic cell-targeted vaccines – hope or hype? Nat Rev Immunol (2014) 14(10):705–11.10.1038/nri3727 PubMed DOI

Alvarez B, Poderoso T, Alonso F, Ezquerra A, Dominguez J, Revilla C. Antigen targeting to APC: from mice to veterinary species. Dev Comp Immunol (2013) 41(2):153–63.10.1016/j.dci.2013.04.021 PubMed DOI

Stanek O, Linhartova I, Majlessi L, Leclerc C, Sebo P. Complexes of streptavidin-fused antigens with biotinylated antibodies targeting receptors on dendritic cell surface: a novel tool for induction of specific T-cell immune responses. Mol Biotechnol (2012) 51(3):221–32.10.1007/s12033-011-9459-6 PubMed DOI

Dong H, Stanek O, Salvador FR, Langer U, Morillon E, Ung C, et al. Induction of protective immunity against Mycobacterium tuberculosis by delivery of ESX antigens into airway dendritic cells. Mucosal Immunol (2013) 6(3):522–34.10.1038/mi.2012.92 PubMed DOI

Wang H, Griffiths MN, Burton DR, Ghazal P. Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. Proc Natl Acad Sci U S A (2000) 97(2):847–52.10.1073/pnas.97.2.847 PubMed DOI PMC

Ejaz A, Ammann CG, Werner R, Huber G, Oberhauser V, Horl S, et al. Targeting viral antigens to CD11c on dendritic cells induces retrovirus-specific T cell responses. PLoS One (2012) 7(9):e45102.10.1371/journal.pone.0045102 PubMed DOI PMC

Castro FV, Tutt AL, White AL, Teeling JL, James S, French RR, et al. CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses. Eur J Immunol (2008) 38(8):2263–73.10.1002/eji.200838302 PubMed DOI

Deloizy C, Bouguyon E, Fossum E, Sebo P, Osicka R, Bole A, et al. Expanding the tools for identifying mononuclear phagocyte subsets in swine: reagents to porcine CD11c and XCR1. Dev Comp Immunol (2016) 65:31–40.10.1016/j.dci.2016.06.015 PubMed DOI

Linghua Z, Xingshan T, Fengzhen Z. In vivo effects of oligodeoxynucleotides containing synthetic immunostimulatory motifs in the immune response to swine streptococcic septicemia vaccine in weaned piglets. Mol Immunol (2007) 44(6):1141–9.10.1016/j.molimm.2006.07.001 PubMed DOI

De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology (2005) 337(1):149–61.10.1016/j.virol.2005.04.004 PubMed DOI

Herve PL, Raliou M, Bourdieu C, Dubuquoy C, Petit-Camurdan A, Bertho N, et al. A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2. J Virol (2014) 88(1):325–38.10.1128/JVI.01141-13 PubMed DOI PMC

Tarus B, Chevalier C, Richard CA, Delmas B, Di Primo C, Slama-Schwok A. Molecular dynamics studies of the nucleoprotein of influenza A virus: role of the protein flexibility in RNA binding. PLoS One (2012) 7(1):e30038.10.1371/journal.pone.0030038 PubMed DOI PMC

Leymarie O, Embury-Hyatt C, Chevalier C, Jouneau L, Moroldo M, Da Costa B, et al. PB1-F2 attenuates virulence of highly pathogenic avian H5N1 influenza virus in chickens. PLoS One (2014) 9(6):e100679.10.1371/journal.pone.0100679 PubMed DOI PMC

Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A (2000) 97(11):6108–13.10.1073/pnas.100133697 PubMed DOI PMC

Szretter KJ, Balish AL, Katz JM. UNIT 15G.1 Influenza: propagation, quantification, and storage. Curr Protoc Microbiol (2006) 3:G:15G.1:15G.1.1–15G.1.22.10.1002/0471729256.mc15g01s3 PubMed DOI

Maisonnasse P, Bouguyon E, Piton G, Ezquerra A, Urien C, Deloizy C, et al. The respiratory DC/macrophage network at steady-state and upon influenza infection in the swine biomedical model. Mucosal Immunol (2016) 9:835–49.10.1038/mi.2015.105 PubMed DOI

Mastin A, Alarcon P, Pfeiffer D, Wood J, Williamson S, Brown I, et al. Prevalence and risk factors for swine influenza virus infection in the English pig population. PLoS Curr (2011) 3:RRN1209.10.1371/currents.RRN1209 PubMed DOI PMC

Li J, Ahmet F, Sullivan LC, Brooks AG, Kent SJ, De Rose R, et al. Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates. Eur J Immunol (2015) 45(3):854–64.10.1002/eji.201445127 PubMed DOI

Henningson JN, Rajao DS, Kitikoon P, Lorusso A, Culhane MR, Lewis NS, et al. Comparative virulence of wild-type H1N1pdm09 influenza A isolates in swine. Vet Microbiol (2015) 176(1–2):40–9.10.1016/j.vetmic.2014.12.021 PubMed DOI

Williams KL. Endotoxins. 2nd ed New York: Marcel Dekker; (2001).

Wei H, Wang S, Zhang D, Hou S, Qian W, Li B, et al. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice. Clin Cancer Res (2009) 15(14):4612–21.10.1158/1078-0432.CCR-08-3321 PubMed DOI

Kurts C. CD11c: not merely a murine DC marker, but also a useful vaccination target. Eur J Immunol (2008) 38(8):2072–5.10.1002/eji.200838645 PubMed DOI

Cohn L, Chatterjee B, Esselborn F, Smed-Sorensen A, Nakamura N, Chalouni C, et al. Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation. J Exp Med (2013) 210(5):1049–63.10.1084/jem.20121251 PubMed DOI PMC

Marquet F, Bonneau M, Pascale F, Urien C, Kang C, Schwartz-Cornil I, et al. Characterization of dendritic cells subpopulations in skin and afferent lymph in the Swine model. PLoS One (2011) 6(1):e16320.10.1371/journal.pone.0016320 PubMed DOI PMC

Marquet F, Vu Manh TP, Maisonnasse P, Elhmouzi-Younes J, Urien C, Bouguyon E, et al. Pig skin includes dendritic cell subsets transcriptomically related to human CD1a and CD14 dendritic cells presenting different migrating behaviors and T cell activation capacities. J Immunol (2014) 193(12):5883–93.10.4049/jimmunol.1303150 PubMed DOI

Vu Manh TP, Elhmouzi-Younes J, Urien C, Ruscanu S, Jouneau L, Bourge M, et al. Defining mononuclear phagocyte subset homology across several distant warm-blooded vertebrates through comparative transcriptomics. Front Immunol (2015) 6:299.10.3389/fimmu.2015.00299 PubMed DOI PMC

Haniffa M, Shin A, Bigley V, McGovern N, Teo P, See P, et al. Human tissues contain CD141(hi) cross-presenting dendritic cells with functional homology to mouse CD103(+) nonlymphoid dendritic cells. Immunity (2012) 37(1):60–73.10.1016/j.immuni.2012.04.012 PubMed DOI PMC

Tamoutounour S, Guilliams M, Montanana Sanchis F, Liu H, Terhorst D, Malosse C, et al. Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin. Immunity (2013) 39(5):925–38.10.1016/j.immuni.2013.10.004 PubMed DOI

Tullett KM, Lahoud MH, Radford KJ. Harnessing human cross-presenting CLEC9A(+)XCR1(+) dendritic cells for immunotherapy. Front Immunol (2014) 5:239.10.3389/fimmu.2014.00239 PubMed DOI PMC

Reuter A, Panozza SE, Macri C, Dumont C, Li J, Liu H, et al. Criteria for dendritic cell receptor selection for efficient antibody-targeted vaccination. J Immunol (2015) 194(6):2696–705.10.4049/jimmunol.1402535 PubMed DOI

De Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, et al. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem (2008) 283(17):11382–7.10.1074/jbc.M800650200 PubMed DOI PMC

Schneemann A, Speir JA, Tan GS, Khayat R, Ekiert DC, Matsuoka Y, et al. A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin. J Virol (2012) 86(21):11686–97.10.1128/JVI.01694-12 PubMed DOI PMC

Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med (1999) 5(10):1157–63.10.1038/13484 PubMed DOI

El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol (2011) 186(2):1022–31.10.4049/jimmunol.0902147 PubMed DOI

Edwards AD, Diebold SS, Slack EM, Tomizawa H, Hemmi H, Kaisho T, et al. Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol (2003) 33(4):827–33.10.1002/eji.200323797 PubMed DOI

Guzylack-Piriou L, Piersma S, McCullough K, Summerfield A. Role of natural interferon-producing cells and T lymphocytes in porcine monocyte-derived dendritic cell maturation. Immunology (2006) 118(1):78–87.10.1111/j.1365-2567.2006.02343.x PubMed DOI PMC

Auray G, Keller I, Python S, Gerber M, Bruggmann R, Ruggli N, et al. Characterization and transcriptomic analysis of porcine blood conventional and plasmacytoid dendritic cells reveals striking species-specific differences. J Immunol (2016) 197(12):4791–806.10.4049/jimmunol.1600672 PubMed DOI

Clausen BE, Stoitzner P. Functional specialization of skin dendritic cell subsets in regulating T cell responses. Front Immunol (2015) 6:534.10.3389/fimmu.2015.00534 PubMed DOI PMC

Caminschi I, Lahoud MH, Shortman K. Enhancing immune responses by targeting antigen to DC. Eur J Immunol (2009) 39(4):931–8.10.1002/eji.200839035 PubMed DOI

Finkelman FD, Lees A, Birnbaum R, Gause WC, Morris SC. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J Immunol (1996) 157(4):1406–14. PubMed

Andrews SF, Kaur K, Pauli NT, Huang M, Huang Y, Wilson PC. High preexisting serological antibody levels correlate with diversification of the influenza vaccine response. J Virol (2015) 89(6):3308–17.10.1128/JVI.02871-14 PubMed DOI PMC

Loeffen WL, Heinen PP, Bianchi AT, Hunneman WA, Verheijden JH. Effect of maternally derived antibodies on the clinical signs and immune response in pigs after primary and secondary infection with an influenza H1N1 virus. Vet Immunol Immunopathol (2003) 92(1–2):23–35.10.1016/S0165-2427(03)00019-9 PubMed DOI